South Korea-based Celltrion Inc. announced that the European Commission has granted marketing authorization to its blood cancer treatment, Truxima, a biosimiliar to Roche’s best-selling cancer drug, Rituxan.
Truxima is the first blood cancer biosimiar approved in Europe. The EC’s approval is effective in 28 European Union members and three European Economic Area countries - Norway, Iceland and Lichtenstein.
It is expected that Truxima will enter the market with a potential 30% reduction on the price of Roche's Rituxan.
Read the Pulse article
